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When I began studying clinical toxicology in 1981, the issue
of gastrointestinal decontamination after acute ingestion
seemed pretty well settled: “universal antidote,” apomor-
phine and salt–w a t e re m e s i sw e r en ol o n g e ru s e d[ 1, 2]; andI
was taught that barring a specific contraindication, the awake
patient was given syrup of ipecac to induce emesis, and the
drowsy or uncooperative patient was lavaged [3]. After
gastric emptying, everyone received activated charcoal
(AC). The only controversy seemed to be over whether one
should add a cathartic to speed gastrointestinal transit [4].
Within a few years, my comfortable assumptions were
upset by several prospective randomized trials that cast
doubt on the value of gastric emptying prior to AC [5–8].
Merigian even challenged the ritual of routine oral AC
when he assigned a subgroup of asymptomatic overdose
patients to observation without charcoal and found no
difference in outcome [8]. At about the same time, case
reports of adverse outcomes in patients given AC began to
appear [9–12]. (Ironically, when reviewing the literature in
preparation for the present article, I found skepticism about
gastrointestinal decontamination dating back to the 1940s.
As summarized by Matthew [13], Harstad and Danish
colleagues reported in 1942 that relatively little phenobar-
bital was recovered by lavage even shortly after overdose
[14] and this, along with their finding of particles of
charcoal in the lungs of patients who died, led them to call
for the abandonment of gastric lavage for poisoning.)
In recent years, my colleagues and I have continued to
debate the value of various methods of gastric decontam-
ination and the role and risks of activated charcoal, and it is
clear to me that the issue remains muddy. Some have taken
a firm stand that no treatment should be recommended that is
notsupportedbyevidencefromarandomizedcontrolledtrial
(RCT). Position statements published jointly by the Amer-
ican Academy of Clinical Toxicology and the European
Association of Poison Centres and Clinical Toxicologists
have adopted a generally conservative view (i.e., lacking
evidence, these procedures should not be used routinely)
[15–18]. Others have argued that quality RCTs are few and
flawed and that we may never have all the evidence we
need to guide management of every case. A number of
thorough and thoughtful reviews and editorials have
summarized the literature and have attempted to provide
guidance for the selected use of gastric emptying or
activated charcoal [19–23].
In this brief review, I will attempt to answer the
following questions about activated charcoal: what is it
and what does it bind to? What do animal studies and
human volunteer studies reveal about its efficacy in
simulated overdose? What evidence is there from case
reports and controlled trials for its benefit in humans? What
are the potential risks of administering activated charcoal?
And finally, how can we put our knowledge about charcoal
to use in managing specific patients?
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The reader wanting a comprehensive and yet very readable
review of the origins of activated charcoal, its physiochem-
ical properties, as well as data on adsorption of various
drugs and poisons, and reported animal and human studies
is directed to Activated Charcoal in Medical Applications,
by David O. Cooney [24]. This excellent book traces the
use of charcoal for medicinal purposes dating as far back as
1550 BC and reviews scientific and clinical studies of
charcoal from the eighteenth century to the present.
Charcoal is produced by heating pulverized carbona-
ceous substances such as sawdust, peat, or coconut shells to
very high temperatures (600-900°C) followed by “activa-
tion” using steam or hot air to erode the internal surfaces of
the product and thereby increase its adsorptive surface area.
Typical surface areas for activated charcoals average of
800-1,200 m
2/g [25]. Thus, a 50-g dose of activated
charcoal has an adsorptive surface area equivalent to about
seven football fields! “Superactivated” charcoals may have
a surface area of 2,800-3,500 m
2/g and can adsorb greater
quantities of drug [26].
Adsorption results from weak intermolecular (Van der
Waals) forces and desorption of the solute can occur if
sufficient charcoal is not given. Ionization and polarity are
important factors in determining adsorption. Strongly
dissociated salts such as sodium chloride or potassium
nitrate are not well adsorbed, while nondissociating solutes
such as mercuric chloride and iodine are adsorbed very well
[27]. Organic compounds are generally well adsorbed and
large poorly water-soluble compounds (e.g., fatty acids) are
better adsorbed to AC than smaller compounds with polar
substituent groups (e.g., alcohols). As pH may affect
ionization, it is not surprising that salicylate is more
completely adsorbed at a low pH, when more of the drug
is in a nonionized state. The opposite is true for a basic
compound such as aniline [28]. In vitro, the maximal
binding capacity of AC for drugs and poisons varies from
35 mg/g AC for potassium cyanide to a whopping
1,800 mg/g of AC for mercuric chloride [29]. A number
of common hypnotic and sedative drugs had maximal
binding in the range of 56-262 mg/g of AC depending on
the drug, the pH, and the dose of AC [30]. The
conventionally accepted optimal ratio of approximately
10:1 (dose of AC/amount of drug ingested by weight) is
based on these and other studies [31], but it is worth noting
that more or less AC may be required depending on the
specific poison. A recent meta-analysis of human volunteer
studies suggests that the optimal ratio of activated charcoal
to drug may be closer to 40:1 [32].
Activated charcoal does not effectively adsorb ferrous
sulfate [33] or lithium carbonate [34]. Despite the famous
claim that in 1811 Bertrand publicly swallowed a lethal
dose of arsenic trioxide mixed with charcoal [35], more
recent studies appear to disprove its effectiveness for this
poison [36]. Studies on ethanol and other alcohols also
report poor adsorption, which is not surprising because
these are small highly water-soluble molecules [37].
However, another possible explanation is that at usual toxic
doses (e.g., more than 25 mL) there is little chance of
achieving a 10:1 ratio by weight of AC to drug. This
argument is supported by an in vitro study in which 5 g AC
was mixed with simulated gastric fluid and varying
amounts of methanol or ethylene glycol [38]. While
charcoal was no match for 100-mL doses of the solvents
(only 26% of methanol and 2% of ethylene glycol was
adsorbed), it adsorbed most of 1-mL dose (59% methanol
and 68% of ethylene glycol adsorbed). The 1-mL dose
corresponds to about a 5:1 ratio of AC/solvent by weight.
So maybe it is really a matter of not enough charcoal.
Animal Studies
A large number of in vivo studies have been carried out in
animals and are well summarized by Cooney [39]. (Further
discussion of these and more recent animal studies is beyond
the scope of this review.) The results vary depending on the
drug, the amount of drug given, the amount of charcoal used,
and the time delay to administration of AC. Cooney writes,
“With almost any substance, if enough charcoal is given
without undue delay, the charcoal will be reasonably
effective in reducing the absorption of that substance.”
Human Volunteer Studies
Human volunteer studies involving oral activated charcoal
have been well summarized by previous authors [16, 21]; I
will highlight a few of them. Curtis gave adult volunteers 24
81-mg aspirin tablets followed 1 h later by 60 g AC in
magnesium sulfate; compared with controls, the charcoal
reduced total salicylate absorption by 43.6% [40]. Tenenbein
reported a 57% reduction in drug absorption by giving 50 g
AC 1 h after a 5-g dose of ampicillin in volunteers [41]. In
another study, 50 g of AC reduced the area under the curve
(AUC) for acetaminophen absorption by 56% if given 1 h
after a 3-g dose of the drug, but only 22% if the AC was
given after 2 h [42]. In a similar study, Green [43]r e p o r t e d
reductions in AUC after a 4-g acetaminophen ingestion of
30.5% and 7.7% by administration of 50 g AC after 1 or 2 h,
respectively. Bond [21] combined the results of numerous
studies into a graph that illustrates the importance of time to
treatment with AC (see Fig. 1).
Treatment with AC more than 1 h after ingestion might
be more effective if the drug ingested has pharmacologic
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most absorption occurs (e.g., aspirin, anticholinergic drugs,
opioids), or is contained in a modified-release preparation
that is designed to slow its absorption. To test this premise,
Green administered atropine 0.01 mg/kg IM 15 min prior to
3.9 g acetaminophen to a group of volunteers and measured
a 47% reduction in AUC when charcoal was given after 1 h
compared to a 20% reduction in AUC for volunteers who
received charcoal but no atropine [44]. Mullins reported a
43% reduction in the AUC of acetaminophen combined
with oxycodone if charcoal was given at 1 h compared with
a 22% and 15% reduction after 2 and 3 h, respectively [45].
More impressive results were obtained for modified-release
drugs: AC given 4 h after ingestion of nine 325-mg enteric-
coated aspirin tablets reduced the AUC by 57% [46], and
AC given at 2 and 4 h after ingestion of 240 mg of
sustained-release verapamil reduced the AUC by 35% and
32%, respectively [47]. Minton reported a 63.3% reduction
in drug absorption from three 200-mg sustained-release
theophylline tablets when charcoal plus sorbitol was
delayed for 6 h [48].
Jurgens performed a meta-analysis of 64 controlled
human volunteer studies, which confirmed the benefit of
AC when given 0-5 min after drug ingestion (median
reduction in drug absorption 88.4%; 25-75 percentile = 65-
96.8%, P<0.00001) and also showed that the effect of AC
continued to be statistically significant when AC was
administered 1 h after drug intake (median reduction 38.4%;
25-75 percentile = 25.4-61.7%, P<0.00001), 2 h after drug
ingestion (median reduction 24.4%; 25-75 percentile = 13.6-
31.5%, P<0.00001), and even up to 4 h after drug intake
(median reduction 27.4%; 25-75 percentile = 21.3-31.5%,
P=0.0006) [32]. The authors pointed out that in one quarter
of the comparisons, a 1-h delay to AC still reduced drug
uptake by nearly 62% and in a quarter of the comparisons, a
4-h delay to AC still reduced drug uptake by over 31%. A
very interesting feature of their study was an analysis of
the reduction in drug absorption plotted against the AC/
drug ratio, which suggested that the optimal dose of AC
may be much greater than the conventional 10:1 ratio
(see Fig. 2). Another intriguing finding was that the
reduction in drug exposure by AC was correlated with the
drug’s volume of distribution (Vd). This is not really
surprising since drugs with a large Vd tend to be nonpolar
and poorly water soluble, physiochemical characteristics
that are likely to increase a compound’s adsorptive binding
to charcoal [27].
Clinical Studies of Activated Charcoal in Patients
with Drug Overdose
Three of the large, prospective RCTs of gastric emptying in
acute poisoning that cast doubt on the use of ipecac-
induced emesis or gastric lavage were not designed to
assess the utility of activated charcoal [5–7]. However,
another early RCT involving 808 drug overdose patients
randomized a subgroup of 451 asymptomatic patients to
receive oral activated charcoal or supportive care only
[8]. No patients showed clinical deterioration in either
group. Obviously, this was a very-low-risk group to begin
with.
What about potentially toxic ingestions? The literature is
conflicting. Two studies measured drug levels in patients
with tricyclic antidepressant overdose and found no
difference between those who received activated charcoal
and those who did not [49, 50]. However, in both of these
studies, patients were first treated with gastric lavage,
which undoubtedly delayed the time to AC administration
and probably forced drug into the small intestine further out
of the reach of charcoal.
Fig. 2 Effectiveness of activated charcoal as a function of the AC/
drug ratio (reproduced from Jurgens et al., with permission [32])
Fig. 1 Impact of the time to activated charcoal administration on
reduction in drug absorption (reproduced from Bond, with permission
[21])
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aminophen overdose of 5 g or more, and who arrived for
treatment within 4 h (median time of arrival, 123 min), to
one of four groups: gastric lavage, oral activated charcoal in
a 10:1 ratio, syrup of ipecac, and no treatment (controls)
[51]. Patients in the charcoal group had the greatest fall in
serum acetaminophen levels. The control group was aban-
doned for ethical reasons after serum acetaminophen levels
increased in four out offive patients. In a retrospective review
of 981 acetaminophen overdoses treated over a 10-year
period, patients who had received activated charcoal were
significantly less likely to have toxic acetaminophen levels
[52]. A prospective observational multi-center study of
patients with acetaminophen overdose whose treatment was
initiated 4 h or later after ingestion found a reduced (but not
statistically significant) incidence of hepatotoxicity (AST or
ALT >1,000) in the group that received activated charcoal
plus N-acetylcysteine (NAC) compared with those that
received only NAC (0/40 in the charcoal group versus 2/17
in controls; P=0.08) [53]. The two groups did not differ in
time to initiating NAC therapy. A larger retrospective
analysis of reports to the American Association of Poison
Control Centers’ Toxic Exposure Surveillance System
(TESS) also found a reduced likelihood of hepatotoxicity
in patients who received both AC and NAC compared with
NAC alone, but these data did not record when NAC
treatment was initiated [54]. If patients arriving later and
therefore at greater risk were judged to be “too late” to
receive charcoal this could have skewed the results in favor
of AC.
Isbister and colleagues employed a complex Bayesian
analysis method using retrospective data collected from a total
of more than 500 patients with citalopram overdose and found
that administration of AC reduced the probability of having a
prolonged QT interval [55, 56]. The same group used
Bayesian methodology and retrospective concentration–time
data to show that administration of AC resulted in a
significant reduction in drug absorption after overdose by
citalopram (22% reduction in bioavailability) and quetiapine
(35% reduction) [57, 58]. Activated charcoal was initiated
after 1 h in most of their patients. Recently, they showed that
a combination of AC and whole bowel irrigation reduced by
29% the amount of drug absorbed and also reduced the peak
drug level after overdoses of venlafaxine [59]. Most of the
venlafaxine patients had taken a sustained-release preparation.
Roberts analyzed cardenolide pharmacokinetics in
patients with acute self-poisoning by ingestion of yellow
oleander (Thevetia peruviana) seeds and found a significant
reduction in the apparent terminal half-life in patients who
received activated charcoal (33.9 h) compared to those who
did not (62.9 h) [60]. However, clinical outcome (mortality)
studies of activated charcoal for yellow oleander seed
poisoning have produced conflicting results [61, 62].
In addition to the controlled trial of AC in a subgroup of
asymptomatic overdose patients described earlier [8], three
other large prospective outcome studies comparing AC with
supportive care are worth mentioning. Merigian found no
difference in outcome for 1,479 overdose patients random-
ized to orally receive AC or supportive care only [63]. The
vast majority of cases (1,266 patients) were not admitted to
the hospital, reflecting the low risk of serious outcome in
most overdoses presenting to the emergency department
(ED). Lopsided numbers in the charcoal (399 patients) and
no charcoal (1,080 patients) group raises questions about
the randomization method (even-odd day allocation).
Cooper randomized 327 patients with acute drug
overdose using a sealed envelope method and found no
differences between AC and supportive care only groups
with respect to length of stay, intensive care unit (ICU)
admission, or mortality [64]. However, most patients were
not very ill (they excluded seven patients with ingestions
judged to be too serious to enter a randomized trial), and
there was only one death (in the no treatment group).
The largest RCT to date was reported last year by
Eddleston and colleagues in The Lancet [62]. They
randomized 4,632 Sri Lankan patients with acute intention-
al self-poisoning (mostly pesticides and yellow oleander
seeds) to receive a single 50 g dose of AC, multiple doses
of AC (six doses of 50 g every 4 h), or supportive care only.
T h e yf o u n dn od i f f e r e n c ei nm o r t a l i t y( t h e i rp r i m a r y
outcome measure) between the three groups. The study
was carried out in secondary receiving hospitals in rural Sri
Lanka where transport time to medical care is often lengthy.
Indeed, patients in the three groups arrived at the hospital
an average of 4.2, 4.2, and 4.3 h after the ingestion,
respectively, which might explain the absence of benefit
from AC. The authors reported that they could not
demonstrate an advantage to charcoal use in a subgroup
of patients who presented earlier. However, only 176
patients arrived within 60 min and only 664 within 2 h,
and the study was not powered to detect a difference in
mortality at these numbers. Moreover, it is not clear how
soon after arrival patients were randomized and received
their first dose of AC. The authors constructed a Forest plot
of outcomes comparing any use of AC versus no use of AC
in 30-min subgroups and found no significant differences;
however, the subgroups were small. Using data reported by
the authors, for patients arriving within 90 min of ingestion, I
calculateda reducedoddsratiofordeath(0.77)ifanycharcoal
was given, but with a 95% confidence of 0.35-1.70.
It remains to be seen what impact this latest study will
have on the use of activated charcoal for poisonings.
Clearly, conditions are different in the rural developing
world. The patient may have to walk or be taken by bicycle
or tractor to a local dispensary, where first aid of variable
quality and consistency may be administered. In many
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forced emesis or gastric lavage with large quantities of
water without airway protection, even in unconscious
patients [65]. To get to a referral hospital may require a few
hours’ drive in a private vehicle or a basic ambulance lacking
advanced life-support capabilities. Thus, in Eddleston’s
patients, a delay to initiation of activated charcoal might also
be viewed as a delay to intensive supportive care and the
patient’s fate may have already been determined before
enrollment in the study.
What are the Risks of Giving Activated Charcoal?
Although charcoal is generally considered a benign treatment,
there are some risks with its use. Many patients vomit and a
few of them aspirate gastric contents into the lungs causing a
pneumonitis. Compliance is unpredictable, and complications
may occur when passing a nasogastric tube to administer the
charcoal. Addition of a cathartic may cause diarrhea and
failure to give a laxative may cause constipation or the
formation of charcoal briquettes in the intestinal tract [66].
Charcoal has been blamed for appendicitis [67] and intestinal
perforation [68] in single case reports.
While most adolescents and adults will drink activated
charcoal voluntarily, the data regarding compliance in
children is inconclusive. Two studies found a high
acceptance rate (83-90%) in children offered AC [69, 70].
In contrast, Kornberg reported that only 21/70 (30%) of
children in the ED with an ingestion voluntarily took oral
charcoal; the rest received it by nasogastric tube [71].
House staff and nurses were instructed to try and get the
child to take the AC willingly, but the authors acknowl-
edged that most of the ED staff believed that children were
unlikely to do so and may not have tried very hard. Another
factor in Kornberg’s study is that nearly half the children
had received syrup of ipecac and may have been unwilling
or unable to tolerate oral charcoal. Another ED study found
that only 44% of children under 6 years old drank AC
willingly [72]. Adding a flavoring agent did not appear to
influence compliance in these children. Various “taste-test”
studies have provided conflicting data about the preferences
of children for AC mixed in chocolate milk, cola, cherry
syrup, orange juice, or ice cream [73–75]. One pediatric
toxicologist advised me that in his experience the most
reliable way to get a child to drink charcoal was to walk
into the room with a big smile and say, “Drink it –- or I’ll
give you a shot!!” (personal communication 2002). Person-
ally, I have not found any of these or other touted methods
fool proof.
Vomiting is the most common complication of AC
administration. Rates of vomiting in adults range from 7%
[76] to 12.5% [77] to 23% [63] and in children from 6.9%
[70] to 16% [71] to 20.4% [78]. Not surprisingly, if syrup
of ipecac preceded the charcoal, the rate of vomiting was
even higher: Kornberg reported that 18/32 children who
had received ipecac vomited after charcoal [71]. Sorbitol,
used as a sweetener and laxative agent, has been suspected
[23, 78] of contributing to emesis but two studies failed to
show an increase in vomiting in patients receiving AC plus
sorbitol compared to those receiving AC alone [77, 78].
One study in adults suggested that acupressure may help
prevent vomiting [79].
Pulmonary aspiration is the most serious potential
complication after AC administration, and cases reported
in the medical literature and the TESS have been well
summarized by Seger [22]. In some cases, aspiration
resulted from accidental insertion of a nasogastric tube into
the trachea instead of the stomach [80, 81]. More commonly,
pulmonary aspiration occurs when the drowsy or convulsing
patient regurgitated gastric contents, including activated
charcoal, into the unprotected airway.
Aspiration of gastric contents can result in acute airway
obstruction, bronchospasm, hypoxemia, and pneumonitis,
regardless of whether activated charcoal is present. One
patient developed a charcoal-containing empyema [10].
Prolonged intubation, death [22], and permanent lung injury
[82] may follow.
H o wc o m m o ni sp u l m o n a r ya s p i r a t i o ni no v e r d o s e
patients? In a retrospective study of 4,562 patients admitted
to the Hunter Area Toxicology Service (HATS) over a 5-year
period,only71patients(1.6%)werediagnosedwithaspiration
pneumonia [83]. Significant risk factors for aspiration
included depressed mental status, emesis, seizure, ingestion
of a tricyclic antidepressant, and a delay of more than 24 h
before admission. However, administration of AC was not
associated with an increased risk of aspiration pneumonitis
(odds ratio 1.01, 95% confidence interval 0.63-1.70). Neither
was ingestion of alcohol, benzodiazepines, or antipsychotics.
The low overall rate of aspiration in this study is consistent
with prospective randomized trials of AC for acute overdose
[8, 63, 64] and patients receiving AC alone in other gastric
emptying studies [5–7]. The rate of aspiration in patients
who are more seriously intoxicated is obviously higher; in
the HATS study 11% of patients admitted to ICU developed
aspiration pneumonia [83]. In another study, 45% of
overdose patients admitted to an ICU with a GCS of less
than eight points developed aspiration [84]. Endotracheal
intubation reduces the risk of aspiration pneumonitis, but
not completely: two (4%) of 50 patients who had been
intubated prior to receiving AC still developed aspiration
pneumonia [85].
Is charcoal aspiration any different from pulmonary
aspiration of gastric contents? In other words, is charcoal
staining of lung tissue simply a marker for the presence of
gastric acid? In 1988, Menzies reported a fatal case of
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multiple dose activated charcoal [11]. Necropsy revealed
charcoal not only in the alveoli but also within alveolar
macrophages and in the sinusoidal histiocytes of the
regional lymph nodes. In another case report the following
year, a 16-year-old woman developed bronchiolitis obliter-
ans and fatal progressive respiratory failure after charcoal
aspiration [12]. Embedded within the bronchiolar scar tissue
werelargeamountsofcharcoalassociatedwithaforeignbody
giant cell reaction. Animal models support the damaging
effect of charcoal in the absence of gastric contents: in rats,
transtracheal injection of activated charcoal into the lungs
caused progressive airway inflammation and obliterative
bronchiolitis [86]. And intratracheal instillation of activated
charcoal in isolated rat lungs resulted in a significant increase
in microvascular permeability compared with sterile water
[87]. In an accompanying editorial, Tomaszewski warned of
charcoal’s “dark side” [88].
What’s the Bottom Line on Charcoal?
We will probably never have all of the evidence we need
from prospective randomized controlled trials to definitive-
ly guide use of activated charcoal for the overdose patient.
There are just too many variables to study: the specific drug
or poison; its formulation (liquid, solid, sustained release);
when it was ingested, and in what quantity; the clinical
condition of the patient; available antidotes or therapeutic
agents; and the quality of available emergency medical care.
More than a decade after the first publication of the American
Academy of Clinical Toxicology (AACT)/European Associ-
ation ofPoisonCentres and Clinical Toxicologists(EAPCCT)
position statements on gut decontamination, practicing med-
ical toxicologists have differing opinions on how to manage a
specific poisoning [20, 89]. The latest AACT/EAPCCT
Position Statement on single dose activated charcoal advises
that we not use AC routinely, but does not provide much
specific guidance for when it should be considered [16].
Greene proposes the following criteria for oral adminis-
tration of AC: (1) the ingestion is potentially toxic, (2) there
are no contraindications to use of AC, (3) the substance is
adsorbed by AC, (4) the substance is likely to still be in the
GI tract when AC is given, (5) the patient is expected to be
able to maintain a patent airway or is already intubated, and
(6) the GI tract is functionally and anatomically intact; and
there is no safer or more effective alternate treatment [23].
Baileypicturesa risk-benefit“gastrointestinaltriangle” whose
three corners are (1) the hazard posed by the ingestion, (2) the
potential benefit of gastrointestinal decontamination, and (3)
the risks of the procedure [90, 91]. Wiegand designed an
algorithm incorporating the risk of aspiration, the potential
toxicity of the substance, and the time since ingestion [92].
The algorithm (presented in abstract form but not yet
published in full) calls for administration of AC up to 4 h
after ingestion of potentially toxic substances or up to 24 h in
special circumstances: e.g., the drug is probably still present
in the stomach (e.g., massive ingestion, anticholinergic, and
salicylate); the poisoning could be lethal despite supportive
care; a very large ingestion requiring multiple doses of AC to
achieve a 10:1 AC/drug ratio; or ingestion of drug packets
(“body packer” or “stuffer”). Wiegand’s list of potentially
lethal drugs includes cardiotoxic agents such as calcium
channel blockers and chloroquine; cytotoxic agents such as
amatoxin-containing mushrooms, colchicine, and chemother-
apeutic agents; and other menacing poisons such as paraquat.
Favors AC AC risky or not needed
Substance
Low toxicity (e.g., a benzodiazepine) X
Highly toxic (e.g., verapamil, colchicine) X
Modified-release (e.g., bupropion SR) X




Drowsy, not intubated X
Airway intact and stable X
Circumstances
Antidote available (e.g., acetaminophen) X
Dose taken is small X
Massive ingestion X
Arrives within 1-2 h of ingestion X
Table 1 Some contributors to
the risk assessment for use of
oral activated charcoal
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importance of assessing each case individually. Based on
personal experience, knowledge of the pharmacology and
toxic behavior of a drug, and the unique circumstances of
the ingestion, we make our best judgment of the value or
risk of GI decontamination. For example, I know that
aspirin may remain in the stomach for several hours—in
one reported case, gastric lavage recovered over 20 g of
salicylate 9 h after an ingestion of 200 aspirin tablets (31%
of the ingested dose) [13]. That is the equivalent of over 60
tablets! As a result, I often advise aggressive gut decon-
tamination even several hours after a large aspirin overdose.
The same goes for ingestion of a modified-release prepa-
ration, especially of a toxic drug such as a calcium channel
blocker. On the other hand, given that most overdoses
involve nonlethal doses of drugs with low to moderate
toxicity, in which GI decontamination is not likely to affect
outcome, I am less enthusiastic about routine use of
charcoal. The decision to use AC in such cases depends
the time since ingestion, the patient’s mental status, and
their willingness to drink the charcoal, as well as an
assessment of the potential toxicity of the ingested drugs.
Table 1 illustrates the role of several variables in the
decision to use oral activated charcoal.
How to manage the patient who meets some of the
“risky” criteria but might still benefit from decontamina-
tion? Bailey presents a hypothetical 16-year-old girl who
ingested up to 28 venlafaxine SR and 28 zaleplon 45 min
prior to arrival in the ED [92]. She has slurred speech but
normal vital signs and a Glasgow Coma Score of 15. This
is a case whose discussion among clinical toxicologists is
likely to induce heated debate. Bailey contends that the girl
may benefit from oral AC since a significant portion of the
venlafaxine probably remains unabsorbed. But there is a
risk that the patient will become drowsy or convulse, which
would increase the likelihood of pulmonary aspiration. For
this reason, many clinicians would favor early endotracheal
intubation followed by nasogastric administration of AC.
Because the ingested venlafaxine is in a sustained-release
preparation, I would also recommend whole bowel irriga-
tion, which may help reduce the total amount absorbed as
well as the peak serum level [59].
Summary
Activated charcoal can effectively bind a wide variety of
drugs and poisons with a few notable exceptions (e.g., iron,
lithium, potassium, and ethanol). Animal and human
volunteer studies, as well as case reports, have shown that
AC can prevent systemic absorption of drugs when given
within 1-2 h of ingestion and perhaps longer after ingestion
of sustained-release preparations. The optimal dose is
probably a 40:1 ratio (by weight) of charcoal to drug,
higher than the conventional 10:1 ratio. Randomized,
controlled trials have failed to demonstrate improved
clinical outcome in overdose patients treated with AC,
and there are risks with its use—most importantly,
pulmonary aspiration of gastric contents. But there are
important flaws in the RCTs reported to date, and they have
not yet cast charcoal into the ash heap of toxicology. I can
think of several lines of future inquiry including the use of a
higher dose ratio of AC to drug (up to 40:1 by weight), the
combination of multiple doses of AC with whole bowel
irrigation for massive ingestions, and late decontamination
after overdose involving sustained-release drugs. Mean-
while, there is enough evidence from in vitro data,
volunteer studies, and case reports to justify the use of oral
AC in selected overdoses.
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